Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keymeulen, B.
Right arrow Articles by Pipeleers, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keymeulen, B.
Right arrow Articles by Pipeleers, D. G.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 45, Issue 12 1814-1821, Copyright © 1996 by American Diabetes Association


ARTICLES

Long-term metabolic control by rat islet grafts depends on the composition of the implant

B Keymeulen, G Korbutt, M De Paepe, F Gorus, G Kloppel and DG Pipeleers
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.

This study examines whether the loss of metabolic control in initially normalized islet transplants can result from the inadequate composition of the donor tissue. Streptozotocin-induced diabetic rats were followed for 64 weeks after the intraportal injection of islet isografts with different composition. The implantation of 2.3 million beta-cells (10(7)/kg body wt) as particles (>100 microm diameter) of primarily insulin-positive (70%) and glucagon-positive (20%) cells succeeded in a long-term normalization of 2-h fasting glycemia, glucose tolerance, and serum fructosamine. The same metabolic control was achieved in animals with short and long durations of diabetes or when grafts were implanted under the kidney capsule. At posttransplantation (PT) week 64, insulin reserves were 60% lower than those in age-matched controls, which may account for the glucose intolerance in a few old recipients. The same type of graft containing 0.7 million beta-cells (4 x 10(6)/kg body wt) corrected these metabolic parameters for more than 12 weeks; the proportionally lower insulin reserves were sufficient for the long-term correction of 2-h fasting glycemia, but did not avoid glucose intolerance in older recipients. When the higher beta-cells number (10(7)/kg body wt) was injected as smaller particles (<100 mpm diameter) of lower purity (55% insulin-positive) and negligible glucagon content (<5% glucagon-positive), the metabolic parameters were also corrected for 12 weeks PT but then progressively returned to overt diabetes (6 of 10) or glucose intolerance (4 of 10). We concluded that long-term metabolic normalization can be achieved by islet implants in the liver or under the kidney capsule. The loss of metabolic control in older animals can be caused by the inadequate composition of the graft, with the number of beta-cells, the proportion of other endocrine and nonendocrine cells, and the particle size as influential variables.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Keymeulen, P. Gillard, C. Mathieu, B. Movahedi, G. Maleux, G. Delvaux, D. Ysebaert, B. Roep, E. Vandemeulebroucke, M. Marichal, et al.
Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft
PNAS, November 14, 2006; 103(46): 17444 - 17449.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Bogdani, K. Suenens, T. Bock, M. Pipeleers-Marichal, P. In't Veld, and D. Pipeleers
Growth and Functional Maturation of {beta}-Cells in Implants of Endocrine Cells Purified From Prenatal Porcine Pancreas
Diabetes, December 1, 2005; 54(12): 3387 - 3394.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Wang, Z. Ling, and D. Pipeleers
Comparison of cellular and medium insulin and GABA content as markers for living {beta}-cells
Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E307 - E313.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. N. Street, J. R.T. Lakey, A.M. J. Shapiro, S. Imes, R. V. Rajotte, E. A. Ryan, J. G. Lyon, T. Kin, J. Avila, T. Tsujimura, et al.
Islet Graft Assessment in the Edmonton Protocol: Implications for Predicting Long-Term Clinical Outcome
Diabetes, December 1, 2004; 53(12): 3107 - 3114.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1996 by the American Diabetes Association.